Evidence map›Paper›PMID 38158497›Full record

ArticleAnnals of surgical oncology2024

Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.

Aikaterini Dedeilia, Thinzar Lwin, Siming Li, Giuseppe Tarantino, Sasha Tunsiricharoengul, Aleigha Lawless, Tatyana Sharova, David Liu, Genevieve M Boland, Sonia Cohen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Melatonin/Sericin Wound Healing Patches: Implications for Melanoma Therapy.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Aikaterini Dedeilia *Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Thinzar LwinDivision of Surgical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Siming LiDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Giuseppe TarantinoBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Sasha TunsiricharoengulHarvard University, Boston, MA, USA.
Aleigha LawlessCancer Center, Massachusetts General Hospital, Boston, MA, USA.
Tatyana SharovaDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
David LiuBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Genevieve M Boland *Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Sonia CohenDivision of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. scohen22@mgh.harvard.edu.
Massachusetts General Hospital · USDana-Farber Cancer Institute · USCity Of Hope National Medical Center · USHarvard University · USMassachusetts Institute of Technology · US

Funding

Institutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7M
NCATS NIH HHS KL2 TR002542
6 · The paper itself

Abstract

backgroundIn the current era of effective adjuvant therapies and de-escalation of surgery, distinguishing which patients with high-risk stage II melanoma are at increased risk of recurrence after excision of the primary lesion is essential to determining appropriate treatment and surveillance plans.

methodsA single-center retrospective study analyzed patients with stage IIB or IIC melanoma. Demographic and tumor data were collected, and genomic analysis of formalin-fixed, paraffin-embedded tissue samples was performed via an internal next-generation sequencing (NGS) platform (SNaPshot). The end points examined were relapse-free survival (RFS), distant metastasis-free survival (DMFS), overall survival (OS), and melanoma-specific survival (MSS). Uni- and multivariable Cox regressions were performed to calculate the hazard ratios.

resultsThe study included 92 patients with a median age of 69 years and a male/female ratio of 2:1. A Breslow depth greater than 4 mm, a higher mitotic rate, an advanced T stage, and a KIT mutation had a negative impact on RFS. A primary lesion in the head and neck, a mitotic rate exceeding 10 mitoses per mm

conclusionTraditional histopathologic factors and specific tumor mutations displayed a significant correlation with disease recurrence and survival for patients with high-risk stage II melanoma. This study supported the use of genomic testing of high-risk stage II melanomas for prognostic prediction and risk stratification.

Indexed as

MelanomaSkin NeoplasmsAgedFemaleHumansMaleNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesSurvival RateCDH1Genetic analysisKITMelanomaPrognostic factorsStage II

Identifiers

PMID38158497
PMCPMC10908640
OpenAlexW4390394559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.